Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8 + T-cell res...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 17; no. 7; pp. 1882 - 1896
Main Authors Xu, Yuexin, Miller, Chris P., Warren, Edus H., Tykodi, Scott S.
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 03.07.2021
Taylor & Francis Group
Subjects
cancer vaccine
Renal cell carcinoma
Review
t cell receptor
tumor antigen
tumor-infiltrating T cell
tumor antigen
tumor-infiltrating T cell
Renal cell carcinoma
cancer vaccine
t cell receptor
Online AccessGet full text
ISSN2164-5515
2164-554X
2164-554X
DOI10.1080/21645515.2020.1870846

Cover

Abstract In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8 + T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.
AbstractList In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8 T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8+ T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8+ T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8+ T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8 + T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.
Author Miller, Chris P.
Warren, Edus H.
Xu, Yuexin
Tykodi, Scott S.
Author_xml – sequence: 1
  givenname: Yuexin
  orcidid: 0000-0002-7140-6505
  surname: Xu
  fullname: Xu, Yuexin
  email: yxu2@fredhutch.org
  organization: Fred Hutchinson Cancer Research Center
– sequence: 2
  givenname: Chris P.
  surname: Miller
  fullname: Miller, Chris P.
  organization: Fred Hutchinson Cancer Research Center
– sequence: 3
  givenname: Edus H.
  orcidid: 0000-0002-9570-2755
  surname: Warren
  fullname: Warren, Edus H.
  organization: University of Washington
– sequence: 4
  givenname: Scott S.
  orcidid: 0000-0002-0399-0965
  surname: Tykodi
  fullname: Tykodi, Scott S.
  organization: University of Washington
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33667140$$D View this record in MEDLINE/PubMed
BookMark eNqFkk1v3CAQhlGVqvlofkIrH3txChgwqFLVaNWPSJF6SaX2hMYYNkQ2bMFOtf--bLxZNT20XEDDO8-M5p1TdBRisAi9IviCYInfUiIY54RfUExLSLZYMvEMneziNefs-9HhTfgxOs_5DpfTYsqEeIGOm0aIljB8gn6s5pRsmKo8wTTnKroKwuTXNtR5Y4133lQ3tbHDUPlxnEOcbm2CzbZyMVXQ30Mwtq8KAYZFZSAZH-IIL9FzB0O25_v7DH379PFm9aW-_vr5anV5XRvesKluFGPcYey4JIw6qgBaTokTAneut5aUpp00xFkJnbVUEUmarscKy172HW7O0NXC7SPc6U3yI6StjuD1QyCmtYY0eTNYXXhdSztHADPmBFEMO0Vt21LOuGS8sN4vrM3cjbY3ZTAJhifQpz_B3-p1vNeSSEUwKYA3e0CKP2ebJz36vJsLBBvnrClTkinWKFGkr_-sdSjy6E0R8EVgUsw5WXeQEKx3a6Af10Dv1kDv16Dkvfsrz_hiro-7lv3w3-wPS7YPxeIRfsU09HqC7RCTS8Vun3Xzb8RvsY7LQw
CitedBy_id crossref_primary_10_3389_fgene_2022_1040421
crossref_primary_10_3390_cancers15092500
crossref_primary_10_1097_PAI_0000000000001101
crossref_primary_10_4111_icu_20220103
crossref_primary_10_1016_j_ucl_2023_01_012
crossref_primary_10_3390_cells11203289
crossref_primary_10_3389_fimmu_2022_1037808
crossref_primary_10_3390_cells13010034
crossref_primary_10_3389_fimmu_2023_1123853
crossref_primary_10_3390_biomedinformatics4030101
crossref_primary_10_17650_1726_9776_2022_18_4_15_24
Cites_doi 10.1097/CJI.0b013e3181876ab3
10.1093/gbe/evt010
10.1016/S1470-2045(11)70259-5
10.1111/j.1348-0421.2007.tb03940.x
10.18632/oncotarget.2922
10.1007/s00262-019-02419-4
10.1200/JCO.1995.13.3.688
10.1002/cncr.23851
10.1016/S0022-5347(01)66661-8
10.1038/nature02240
10.1038/nrc3982
10.1182/blood.V93.12.4309
10.1158/0008-5472.CAN-16-0274
10.1186/s40425-015-0055-3
10.1126/scitranslmed.aaf8621
10.1097/01.cji.0000211318.22902.ec
10.1038/sj.bjc.6602776
10.1016/j.semcancer.2014.08.002
10.1016/j.cell.2014.12.033
10.1111/j.1349-7006.2006.00231.x
10.1158/1078-0432.CCR-08-0668
10.1158/0008-5472.CAN-05-4303
10.18632/oncotarget.15064
10.1200/JCO.1999.17.7.2105
10.4049/jimmunol.163.1.483
10.1084/jem.182.2.459
10.1172/JCI121476
10.1172/JCI34409C1
10.1111/j.1349-7006.2007.00631.x
10.1158/1078-0432.CCR-15-0580
10.1038/s41467-019-12441-w
10.1038/nm.2883
10.1038/srep29794
10.1155/2013/871936
10.1038/s41590-019-0578-8
10.1200/JCO.19.02105
10.1158/1078-0432.CCR-05-2253
10.1016/S1470-2045(17)30516-8
10.1056/NEJMoa1510665
10.1200/JCO.2020.38.15_suppl.5069
10.1056/NEJMoa1816047
10.1097/CJI.0b013e318183db02
10.1158/0008-5472.CAN-05-3905
10.1097/CJI.0b013e3181ace876
10.1038/s41591-020-1044-8
10.1158/1078-0432.CCR-10-2082
10.1056/NEJMoa1712126
10.1097/CJI.0000000000000301
10.4049/jimmunol.151.8.4209
10.1158/0008-5472.CAN-15-3139
10.1309/1F99-BPDY-7DHH-9G97
10.1016/j.ymthe.2019.10.001
10.4049/jimmunol.1103028
10.1002/ijc.22018
10.1038/sj.bjc.6690355
10.1111/1744-9987.12694
10.1158/1078-0432.CCR-05-2732
10.1016/S1074-7613(00)80163-6
10.1084/jem.183.6.2533
10.1186/s12967-017-1254-0
10.1097/CJI.0b013e31819d297e
10.1084/jem.193.10.1189
10.1016/j.cell.2017.04.016
10.1038/modpathol.3800588
10.1200/JCO.1999.17.8.2530
10.1038/s41568-019-0162-4
10.1038/sj.bjc.6602386
10.1158/1078-0432.CCR-06-2599
10.1097/CJI.0b013e3181833818
10.1200/JCO.2020.38.15_suppl.5009
10.4161/21645515.2014.983857
10.1038/s41416-018-0064-3
10.1158/1078-0432.CCR-14-2926
10.1056/NEJMoa1215134
10.1056/NEJMoa1816714
10.1200/JCO.18.02424
10.1016/j.ebiom.2019.01.063
10.1016/S0022-5347(05)67889-5
10.1593/tlo.13256
10.1002/cti2.1049
10.1038/nature12634
10.5114/wo.2013.34613
10.1186/s13059-016-1092-z
10.1007/s00262-016-1915-5
10.1200/JCO.2020.38.15_suppl.102
10.1007/s00262-010-0935-9
10.1016/j.immuni.2016.05.001
10.1172/jci.insight.122467
10.1038/bjc.1990.20
10.1016/S1535-6108(02)00071-5
10.1038/s41591-020-0839-y
10.1002/ijc.10518
10.1158/0008-5472.CAN-03-4005
10.1128/JVI.00646-08
10.1016/S1470-2045(16)30408-9
10.3389/fonc.2013.00185
10.1038/ni.1790
10.1186/1479-5876-7-2
10.1097/CJI.0b013e3181d75820
10.1084/jem.183.6.2501
10.4161/onci.21356
10.1158/1078-0432.CCR-19-2427
10.1053/hupa.2002.29682
10.1084/jem.190.12.1793
10.1007/s00262-007-0419-8
10.1186/s40425-019-0621-1
10.1002/jgm.397
10.1038/mt.2013.17
10.18632/oncotarget.17666
10.1038/sj.bjc.6690524
10.1007/s00262-016-1917-3
10.1186/1479-5876-8-8
10.1002/cncr.24263
10.1016/S0022-5347(17)73147-3
10.4161/onci.23849
10.1158/1078-0432.CCR-12-3847
10.1038/bjc.2013.90
10.1016/j.cell.2017.11.043
10.1158/0008-5472.CAN-16-2490
10.1002/ijc.22256
10.1007/BF02602776
10.1111/j.1365-2567.2006.02338.x
10.3892/mco.2012.40
10.1073/pnas.86.18.7159
10.1038/onc.2011.179
10.1126/scitranslmed.aag1209
10.1038/nature23477
10.1016/S0002-9440(10)64038-2
10.1007/s00262-004-0581-1
10.1126/science.aba7365
10.1093/intimm/dxn063
10.1056/NEJMc1713444
10.1158/0008-5472.CAN-05-0120
10.1016/j.molimm.2008.09.032
10.1136/jitc-2020-000928
10.1200/JCO.2019.37.15_suppl.4568
10.1093/oxfordjournals.annonc.a058239
10.1038/nm730
10.1038/nature12222
10.1016/0959-8049(94)90179-1
10.1097/00002371-199201000-00001
10.1038/s41591-018-0053-3
10.1002/ijc.2910380406
10.1200/JCO.2010.32.2537
10.1016/j.cell.2019.07.009
10.1182/blood-2015-12-686725
10.1200/JCO.2002.20.1.289
10.4049/jimmunol.162.3.1730
10.3322/caac.21551
ContentType Journal Article
Copyright 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021
2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 The Author(s)
Copyright_xml – notice: 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021
– notice: 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 The Author(s)
DBID 0YH
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1080/21645515.2020.1870846
DatabaseName Taylor & Francis Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Y. XU ET AL
EISSN 2164-554X
EndPage 1896
ExternalDocumentID oai_doaj_org_article_fdeb72bf1a044f61940f92e772545845
PMC8189101
33667140
10_1080_21645515_2020_1870846
1870846
Genre Review
Journal Article
GrantInformation_xml – fundername: Cancer Research Institute
GroupedDBID ---
00X
0YH
30N
4.4
53G
AALUX
ABEIZ
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AEXWM
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
DGEBU
DIK
EBS
H13
HYE
IPNFZ
KYCEM
LJTGL
M4Z
O9-
RIG
RPM
TDBHL
TFL
TFW
TTHFI
AAYXX
CITATION
NPM
7X8
5PM
AQTUD
GROUPED_DOAJ
ID FETCH-LOGICAL-c534t-39445f00f58142f29aa7521f660bfdee1702f8c1fe8abee291813bd0908d8db03
IEDL.DBID DOA
ISSN 2164-5515
2164-554X
IngestDate Fri Sep 19 03:42:11 EDT 2025
Thu Aug 21 18:08:21 EDT 2025
Fri Jul 11 07:15:30 EDT 2025
Thu Apr 03 06:59:17 EDT 2025
Thu Apr 24 23:02:52 EDT 2025
Tue Jul 01 02:46:13 EDT 2025
Wed Dec 25 09:06:35 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords tumor antigen
tumor-infiltrating T cell
Renal cell carcinoma
cancer vaccine
t cell receptor
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-39445f00f58142f29aa7521f660bfdee1702f8c1fe8abee291813bd0908d8db03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-9570-2755
0000-0002-7140-6505
0000-0002-0399-0965
OpenAccessLink https://doaj.org/article/fdeb72bf1a044f61940f92e772545845
PMID 33667140
PQID 2498494396
PQPubID 23479
PageCount 15
ParticipantIDs proquest_miscellaneous_2498494396
pubmed_primary_33667140
crossref_primary_10_1080_21645515_2020_1870846
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189101
doaj_primary_oai_doaj_org_article_fdeb72bf1a044f61940f92e772545845
informaworld_taylorfrancis_310_1080_21645515_2020_1870846
crossref_citationtrail_10_1080_21645515_2020_1870846
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-03
PublicationDateYYYYMMDD 2021-07-03
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-03
  day: 03
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2021
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_2_28_1
e_1_3_2_20_1
e_1_3_2_66_1
e_1_3_2_130_1
e_1_3_2_43_1
e_1_3_2_85_1
e_1_3_2_24_1
e_1_3_2_47_1
e_1_3_2_89_1
e_1_3_2_146_1
Gaudin C (e_1_3_2_15_1) 1999; 162
e_1_3_2_127_1
Gaudin C (e_1_3_2_37_1) 1995; 55
e_1_3_2_62_1
e_1_3_2_104_1
e_1_3_2_142_1
e_1_3_2_81_1
e_1_3_2_123_1
e_1_3_2_108_1
e_1_3_2_16_1
e_1_3_2_39_1
e_1_3_2_7_1
e_1_3_2_31_1
e_1_3_2_54_1
e_1_3_2_77_1
e_1_3_2_12_1
e_1_3_2_35_1
e_1_3_2_58_1
e_1_3_2_96_1
e_1_3_2_3_1
e_1_3_2_92_1
e_1_3_2_116_1
e_1_3_2_50_1
e_1_3_2_73_1
e_1_3_2_131_1
e_1_3_2_112_1
e_1_3_2_154_1
e_1_3_2_139_1
e_1_3_2_29_1
e_1_3_2_152_1
e_1_3_2_21_1
e_1_3_2_44_1
e_1_3_2_63_1
e_1_3_2_86_1
e_1_3_2_25_1
e_1_3_2_48_1
e_1_3_2_67_1
e_1_3_2_126_1
e_1_3_2_149_1
e_1_3_2_40_1
e_1_3_2_82_1
e_1_3_2_103_1
e_1_3_2_122_1
e_1_3_2_145_1
e_1_3_2_107_1
e_1_3_2_17_1
e_1_3_2_2_1
e_1_3_2_55_1
e_1_3_2_141_1
e_1_3_2_32_1
e_1_3_2_74_1
e_1_3_2_6_1
e_1_3_2_13_1
e_1_3_2_59_1
e_1_3_2_97_1
e_1_3_2_78_1
e_1_3_2_93_1
e_1_3_2_115_1
e_1_3_2_138_1
e_1_3_2_157_1
e_1_3_2_51_1
e_1_3_2_111_1
e_1_3_2_134_1
e_1_3_2_153_1
e_1_3_2_70_1
e_1_3_2_119_1
Weinschenk T (e_1_3_2_135_1) 2002; 62
e_1_3_2_49_1
e_1_3_2_151_1
e_1_3_2_41_1
e_1_3_2_87_1
e_1_3_2_22_1
e_1_3_2_64_1
e_1_3_2_45_1
e_1_3_2_26_1
e_1_3_2_68_1
e_1_3_2_148_1
e_1_3_2_83_1
e_1_3_2_121_1
e_1_3_2_60_1
e_1_3_2_102_1
e_1_3_2_144_1
e_1_3_2_106_1
e_1_3_2_129_1
Su Z (e_1_3_2_137_1) 2003; 63
e_1_3_2_9_1
e_1_3_2_18_1
Weidmann E (e_1_3_2_38_1) 1993; 53
e_1_3_2_10_1
e_1_3_2_33_1
e_1_3_2_52_1
e_1_3_2_75_1
e_1_3_2_140_1
e_1_3_2_5_1
e_1_3_2_14_1
Nakano O (e_1_3_2_36_1) 2001; 61
e_1_3_2_56_1
e_1_3_2_79_1
e_1_3_2_98_1
e_1_3_2_114_1
e_1_3_2_94_1
e_1_3_2_110_1
e_1_3_2_156_1
e_1_3_2_71_1
e_1_3_2_90_1
e_1_3_2_133_1
e_1_3_2_118_1
e_1_3_2_27_1
e_1_3_2_42_1
e_1_3_2_65_1
e_1_3_2_88_1
Brossart P (e_1_3_2_125_1) 2001; 61
e_1_3_2_150_1
e_1_3_2_23_1
e_1_3_2_46_1
e_1_3_2_69_1
Vissers JL (e_1_3_2_100_1) 1999; 59
e_1_3_2_80_1
e_1_3_2_101_1
e_1_3_2_124_1
e_1_3_2_147_1
e_1_3_2_61_1
e_1_3_2_84_1
e_1_3_2_105_1
e_1_3_2_120_1
e_1_3_2_143_1
e_1_3_2_128_1
e_1_3_2_109_1
e_1_3_2_8_1
e_1_3_2_19_1
e_1_3_2_30_1
e_1_3_2_76_1
e_1_3_2_11_1
e_1_3_2_53_1
e_1_3_2_34_1
e_1_3_2_4_1
e_1_3_2_57_1
e_1_3_2_99_1
e_1_3_2_113_1
e_1_3_2_136_1
e_1_3_2_95_1
e_1_3_2_132_1
e_1_3_2_155_1
e_1_3_2_72_1
e_1_3_2_91_1
e_1_3_2_117_1
References_xml – ident: e_1_3_2_113_1
  doi: 10.1097/CJI.0b013e3181876ab3
– ident: e_1_3_2_64_1
  doi: 10.1093/gbe/evt010
– ident: e_1_3_2_130_1
  doi: 10.1016/S1470-2045(11)70259-5
– ident: e_1_3_2_88_1
  doi: 10.1111/j.1348-0421.2007.tb03940.x
– ident: e_1_3_2_117_1
  doi: 10.18632/oncotarget.2922
– ident: e_1_3_2_152_1
  doi: 10.1007/s00262-019-02419-4
– ident: e_1_3_2_22_1
  doi: 10.1200/JCO.1995.13.3.688
– ident: e_1_3_2_24_1
  doi: 10.1002/cncr.23851
– ident: e_1_3_2_11_1
  doi: 10.1016/S0022-5347(01)66661-8
– ident: e_1_3_2_21_1
  doi: 10.1038/nature02240
– ident: e_1_3_2_119_1
  doi: 10.1038/nrc3982
– volume: 61
  start-page: 6846
  year: 2001
  ident: e_1_3_2_125_1
  article-title: The epithelial tumor antigen muc1 is expressed in hematological malignancies and is recognized by muc1-specific cytotoxic t-lymphocytes
  publication-title: Cancer Res
– ident: e_1_3_2_123_1
  doi: 10.1182/blood.V93.12.4309
– ident: e_1_3_2_50_1
  doi: 10.1158/0008-5472.CAN-16-0274
– ident: e_1_3_2_94_1
  doi: 10.1186/s40425-015-0055-3
– ident: e_1_3_2_142_1
  doi: 10.1126/scitranslmed.aaf8621
– ident: e_1_3_2_76_1
  doi: 10.1097/01.cji.0000211318.22902.ec
– ident: e_1_3_2_105_1
  doi: 10.1038/sj.bjc.6602776
– ident: e_1_3_2_97_1
  doi: 10.1016/j.semcancer.2014.08.002
– ident: e_1_3_2_30_1
  doi: 10.1016/j.cell.2014.12.033
– ident: e_1_3_2_33_1
  doi: 10.1111/j.1349-7006.2006.00231.x
– ident: e_1_3_2_81_1
  doi: 10.1158/1078-0432.CCR-08-0668
– ident: e_1_3_2_46_1
  doi: 10.1158/0008-5472.CAN-05-4303
– ident: e_1_3_2_39_1
  doi: 10.18632/oncotarget.15064
– ident: e_1_3_2_23_1
  doi: 10.1200/JCO.1999.17.7.2105
– ident: e_1_3_2_19_1
  doi: 10.4049/jimmunol.163.1.483
– ident: e_1_3_2_42_1
  doi: 10.1084/jem.182.2.459
– ident: e_1_3_2_73_1
  doi: 10.1172/JCI121476
– ident: e_1_3_2_70_1
  doi: 10.1172/JCI34409C1
– ident: e_1_3_2_90_1
  doi: 10.1111/j.1349-7006.2007.00631.x
– volume: 55
  start-page: 685
  year: 1995
  ident: e_1_3_2_37_1
  article-title: In vivo local expansion of clonal t cell subpopulations in renal cell carcinoma
  publication-title: Cancer Res
– ident: e_1_3_2_116_1
  doi: 10.1158/1078-0432.CCR-15-0580
– ident: e_1_3_2_146_1
  doi: 10.1038/s41467-019-12441-w
– ident: e_1_3_2_92_1
  doi: 10.1038/nm.2883
– ident: e_1_3_2_134_1
  doi: 10.1038/srep29794
– ident: e_1_3_2_122_1
  doi: 10.1155/2013/871936
– ident: e_1_3_2_156_1
  doi: 10.1038/s41590-019-0578-8
– ident: e_1_3_2_57_1
  doi: 10.1200/JCO.19.02105
– ident: e_1_3_2_75_1
  doi: 10.1158/1078-0432.CCR-05-2253
– ident: e_1_3_2_59_1
  doi: 10.1016/S1470-2045(17)30516-8
– ident: e_1_3_2_52_1
  doi: 10.1056/NEJMoa1510665
– ident: e_1_3_2_58_1
  doi: 10.1200/JCO.2020.38.15_suppl.5069
– ident: e_1_3_2_7_1
  doi: 10.1056/NEJMoa1816047
– ident: e_1_3_2_138_1
  doi: 10.1097/CJI.0b013e318183db02
– ident: e_1_3_2_86_1
  doi: 10.1158/0008-5472.CAN-05-3905
– ident: e_1_3_2_84_1
  doi: 10.1097/CJI.0b013e3181ace876
– ident: e_1_3_2_62_1
  doi: 10.1038/s41591-020-1044-8
– ident: e_1_3_2_85_1
  doi: 10.1158/1078-0432.CCR-10-2082
– volume: 63
  start-page: 2127
  year: 2003
  ident: e_1_3_2_137_1
  article-title: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor rna-transfected dendritic cells
  publication-title: Cancer Res
– ident: e_1_3_2_5_1
  doi: 10.1056/NEJMoa1712126
– ident: e_1_3_2_102_1
  doi: 10.1097/CJI.0000000000000301
– ident: e_1_3_2_13_1
  doi: 10.4049/jimmunol.151.8.4209
– ident: e_1_3_2_71_1
  doi: 10.1158/0008-5472.CAN-15-3139
– ident: e_1_3_2_118_1
  doi: 10.1309/1F99-BPDY-7DHH-9G97
– ident: e_1_3_2_150_1
  doi: 10.1016/j.ymthe.2019.10.001
– ident: e_1_3_2_40_1
  doi: 10.4049/jimmunol.1103028
– ident: e_1_3_2_108_1
  doi: 10.1002/ijc.22018
– ident: e_1_3_2_121_1
  doi: 10.1038/sj.bjc.6690355
– ident: e_1_3_2_89_1
  doi: 10.1111/1744-9987.12694
– ident: e_1_3_2_114_1
  doi: 10.1158/1078-0432.CCR-05-2732
– ident: e_1_3_2_17_1
  doi: 10.1016/S1074-7613(00)80163-6
– ident: e_1_3_2_43_1
  doi: 10.1084/jem.183.6.2533
– ident: e_1_3_2_126_1
  doi: 10.1186/s12967-017-1254-0
– ident: e_1_3_2_83_1
  doi: 10.1097/CJI.0b013e31819d297e
– ident: e_1_3_2_18_1
  doi: 10.1084/jem.193.10.1189
– ident: e_1_3_2_29_1
  doi: 10.1016/j.cell.2017.04.016
– ident: e_1_3_2_131_1
  doi: 10.1038/modpathol.3800588
– ident: e_1_3_2_3_1
  doi: 10.1200/JCO.1999.17.8.2530
– ident: e_1_3_2_72_1
  doi: 10.1038/s41568-019-0162-4
– ident: e_1_3_2_10_1
  doi: 10.1038/sj.bjc.6602386
– ident: e_1_3_2_47_1
  doi: 10.1158/1078-0432.CCR-06-2599
– ident: e_1_3_2_91_1
  doi: 10.1097/CJI.0b013e3181833818
– ident: e_1_3_2_61_1
  doi: 10.1200/JCO.2020.38.15_suppl.5009
– ident: e_1_3_2_136_1
  doi: 10.4161/21645515.2014.983857
– volume: 62
  start-page: 5818
  issue: 20
  year: 2002
  ident: e_1_3_2_135_1
  article-title: Integrated functional genomics approach for the design of patient-individual antitumor vaccines
  publication-title: Cancer Res
– ident: e_1_3_2_55_1
  doi: 10.1038/s41416-018-0064-3
– ident: e_1_3_2_31_1
  doi: 10.1158/1078-0432.CCR-14-2926
– ident: e_1_3_2_141_1
  doi: 10.1056/NEJMoa1215134
– ident: e_1_3_2_6_1
  doi: 10.1056/NEJMoa1816714
– ident: e_1_3_2_144_1
  doi: 10.1200/JCO.18.02424
– ident: e_1_3_2_68_1
  doi: 10.1016/j.ebiom.2019.01.063
– ident: e_1_3_2_4_1
  doi: 10.1016/S0022-5347(05)67889-5
– ident: e_1_3_2_48_1
  doi: 10.1593/tlo.13256
– ident: e_1_3_2_147_1
  doi: 10.1002/cti2.1049
– ident: e_1_3_2_53_1
  doi: 10.1038/nature12634
– ident: e_1_3_2_9_1
  doi: 10.5114/wo.2013.34613
– ident: e_1_3_2_34_1
  doi: 10.1186/s13059-016-1092-z
– ident: e_1_3_2_79_1
  doi: 10.1007/s00262-016-1915-5
– ident: e_1_3_2_145_1
  doi: 10.1200/JCO.2020.38.15_suppl.102
– volume: 61
  start-page: 5132
  year: 2001
  ident: e_1_3_2_36_1
  article-title: Proliferative activity of intratumoral cd8(+) t-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity
  publication-title: Cancer Res
– ident: e_1_3_2_87_1
  doi: 10.1007/s00262-010-0935-9
– ident: e_1_3_2_49_1
  doi: 10.1016/j.immuni.2016.05.001
– ident: e_1_3_2_153_1
  doi: 10.1172/jci.insight.122467
– ident: e_1_3_2_107_1
  doi: 10.1038/bjc.1990.20
– ident: e_1_3_2_98_1
  doi: 10.1016/S1535-6108(02)00071-5
– ident: e_1_3_2_60_1
  doi: 10.1038/s41591-020-0839-y
– ident: e_1_3_2_101_1
  doi: 10.1002/ijc.10518
– ident: e_1_3_2_132_1
  doi: 10.1158/0008-5472.CAN-03-4005
– ident: e_1_3_2_66_1
  doi: 10.1128/JVI.00646-08
– ident: e_1_3_2_93_1
  doi: 10.1016/S1470-2045(16)30408-9
– ident: e_1_3_2_112_1
  doi: 10.3389/fonc.2013.00185
– ident: e_1_3_2_45_1
  doi: 10.1038/ni.1790
– volume: 59
  start-page: 5554
  year: 1999
  ident: e_1_3_2_100_1
  article-title: The renal cell carcinoma-associated antigen g250 encodes a human leukocyte antigen (hla)-a2.1-restricted epitope recognized by cytotoxic t lymphocytes
  publication-title: Cancer Res
– ident: e_1_3_2_82_1
  doi: 10.1186/1479-5876-7-2
– ident: e_1_3_2_115_1
  doi: 10.1097/CJI.0b013e3181d75820
– ident: e_1_3_2_14_1
  doi: 10.1084/jem.183.6.2501
– ident: e_1_3_2_41_1
  doi: 10.4161/onci.21356
– ident: e_1_3_2_95_1
  doi: 10.1158/1078-0432.CCR-19-2427
– ident: e_1_3_2_120_1
  doi: 10.1053/hupa.2002.29682
– ident: e_1_3_2_20_1
  doi: 10.1084/jem.190.12.1793
– ident: e_1_3_2_109_1
  doi: 10.1007/s00262-007-0419-8
– ident: e_1_3_2_35_1
  doi: 10.1186/s40425-019-0621-1
– ident: e_1_3_2_129_1
  doi: 10.1002/jgm.397
– ident: e_1_3_2_77_1
  doi: 10.1038/mt.2013.17
– ident: e_1_3_2_139_1
  doi: 10.18632/oncotarget.17666
– ident: e_1_3_2_67_1
  doi: 10.1038/sj.bjc.6690524
– ident: e_1_3_2_106_1
  doi: 10.1007/s00262-016-1917-3
– ident: e_1_3_2_80_1
  doi: 10.1186/1479-5876-8-8
– ident: e_1_3_2_133_1
  doi: 10.1002/cncr.24263
– ident: e_1_3_2_8_1
  doi: 10.1016/S0022-5347(17)73147-3
– ident: e_1_3_2_51_1
  doi: 10.4161/onci.23849
– ident: e_1_3_2_32_1
  doi: 10.1158/1078-0432.CCR-12-3847
– ident: e_1_3_2_78_1
  doi: 10.1038/bjc.2013.90
– ident: e_1_3_2_155_1
  doi: 10.1016/j.cell.2017.11.043
– ident: e_1_3_2_28_1
  doi: 10.1158/0008-5472.CAN-16-2490
– ident: e_1_3_2_65_1
  doi: 10.1002/ijc.22256
– ident: e_1_3_2_16_1
  doi: 10.1007/BF02602776
– ident: e_1_3_2_111_1
  doi: 10.1111/j.1365-2567.2006.02338.x
– ident: e_1_3_2_104_1
  doi: 10.3892/mco.2012.40
– ident: e_1_3_2_127_1
  doi: 10.1073/pnas.86.18.7159
– ident: e_1_3_2_69_1
  doi: 10.1038/onc.2011.179
– volume: 53
  start-page: 4745
  year: 1993
  ident: e_1_3_2_38_1
  article-title: Evidence for oligoclonal t-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes
  publication-title: Cancer Res
– ident: e_1_3_2_148_1
  doi: 10.1126/scitranslmed.aag1209
– ident: e_1_3_2_157_1
  doi: 10.1038/nature23477
– ident: e_1_3_2_99_1
  doi: 10.1016/S0002-9440(10)64038-2
– ident: e_1_3_2_128_1
  doi: 10.1007/s00262-004-0581-1
– ident: e_1_3_2_151_1
  doi: 10.1126/science.aba7365
– ident: e_1_3_2_110_1
  doi: 10.1093/intimm/dxn063
– ident: e_1_3_2_56_1
  doi: 10.1056/NEJMc1713444
– ident: e_1_3_2_103_1
  doi: 10.1158/0008-5472.CAN-05-0120
– ident: e_1_3_2_124_1
  doi: 10.1016/j.molimm.2008.09.032
– ident: e_1_3_2_140_1
  doi: 10.1136/jitc-2020-000928
– ident: e_1_3_2_74_1
  doi: 10.1200/JCO.2019.37.15_suppl.4568
– ident: e_1_3_2_26_1
  doi: 10.1093/oxfordjournals.annonc.a058239
– ident: e_1_3_2_44_1
  doi: 10.1038/nm730
– ident: e_1_3_2_54_1
  doi: 10.1038/nature12222
– ident: e_1_3_2_27_1
  doi: 10.1016/0959-8049(94)90179-1
– ident: e_1_3_2_12_1
  doi: 10.1097/00002371-199201000-00001
– ident: e_1_3_2_63_1
  doi: 10.1038/s41591-018-0053-3
– ident: e_1_3_2_96_1
  doi: 10.1002/ijc.2910380406
– ident: e_1_3_2_143_1
  doi: 10.1200/JCO.2010.32.2537
– ident: e_1_3_2_154_1
  doi: 10.1016/j.cell.2019.07.009
– ident: e_1_3_2_149_1
  doi: 10.1182/blood-2015-12-686725
– ident: e_1_3_2_25_1
  doi: 10.1200/JCO.2002.20.1.289
– volume: 162
  start-page: 1730
  year: 1999
  ident: e_1_3_2_15_1
  article-title: A hsp70–2 mutation recognized by ctl on a human renal cell carcinoma
  publication-title: J Immunol
  doi: 10.4049/jimmunol.162.3.1730
– ident: e_1_3_2_2_1
  doi: 10.3322/caac.21551
SSID ssj0000702466
Score 2.3122442
SecondaryResourceType review_article
Snippet In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1882
SubjectTerms cancer vaccine
Renal cell carcinoma
Review
t cell receptor
tumor antigen
tumor-infiltrating T cell
SummonAdditionalLinks – databaseName: Taylor & Francis Open Access
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELagCIkLYlkehV1kJK7edWzn4SOsqCokOLUSPVl2Yi-VlmS1aQ_998wkTtVUoB64OrY18Yw9M_bMN4R84k7rvFSC6ayqmHI2Y9bpknGrrfKFclmC-c7ff2Tzpfr2Mx2iCdsYVok-dOiBIrqzGje3de0QEXctwMQHRZ-CdyegCSQOlOhj8kTkoG9ApPlqvr9mAYkW_YsljmI4bMjj-ddMIw3VAfkfwZj-zRg9jqk8UFKzF-R5tC7p514czsgjX78kT_t6k7tzsopoTBTTiLYtbQKFhUU8ToYZlxg1RBcM7_LpGvNGYnbWjgJVdIgWoDCDvet7lViJqG5-21dkOfu6uJmzWFuBlalUG4b5sGngPKRFokQQ2tocNHnIMu5C5X0C6xaKMgm-sM57ocESkK7imhdVUTkuX5NJ3dT-LaEWDlXrpANXs1AwAThwLsgQQmJTlYdqStSwnqaMwONY_-LOJBGfdGCDQTaYyIYpudoPu--RN04N-ILM2ndG4OyuoXm4NXEfGvg3lwsHtHEFxCZa8aCFBx8DXxBVOiX6kNVm092bhL7IiZEnCPg4yIWBTYp8sLVvtq0BH7dQGmw_6POml5M9mVJmGaImTkk-kqDRf4y_1OtfHRA4GFtg7SXv_oPm9-SZwCgdvLCWF2Syedj6SzCzNu5Dt5H-ACpRG5o
  priority: 102
  providerName: Taylor & Francis
Title Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
URI https://www.tandfonline.com/doi/abs/10.1080/21645515.2020.1870846
https://www.ncbi.nlm.nih.gov/pubmed/33667140
https://www.proquest.com/docview/2498494396
https://pubmed.ncbi.nlm.nih.gov/PMC8189101
https://doaj.org/article/fdeb72bf1a044f61940f92e772545845
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELboSki9VFBaWAorV-rVxbEdxz62PLRQ0RNIcLLsxBZIkEWwe-DfdyaPVRYh7aWXHBwnsmcm8Tf2zDeE_ODB2qJUglldVUwFr5kPtmTcW6-iUUFnmO98-VdPr9XFTX4zKPWFMWEtPXAruKNUxVCIkDLPlUroc_NkRQRQiEc-qmEv5ZYPnKnmH1zA2tMcVArwBxjAgrxP3zH8CNuwCdxDAU1gsgYB8GBhavj737CXvodB34ZSDtamsy3yqQOV9Fc7mW2yEevPZLMtM_m6Q247EiaK2UOLFzpLFOSJNJwMEy0xWIheMdzCp_eYLtIlZb1SGBXtgwQovME_tL1KLEBUzx79F3J9dnp1PGVdSQVW5lLNGabB5onzlJtMiSSs9wUs4ElrHkDSMQO5JVNmKRofYhQWAIAMFQjYVKYKXH4lo3pWxz1CPfxLfZAB9GBAMRr8tpBkSqCpXBWpGhPVy9OVHd84lr14cFlHS9qrwaEaXKeGMfm5fOypJdxY98BvVNayM_JlNw1gRa6zIrfOisbEDlXt5s12SWprmzi5ZgDfe7tw8G2iHnwdZ4sXB66tURYgH_TZbe1kOUwptUayxDEpVixoZR6rd-r7u4b_GzAWgLxs_39M_Bv5KDBKBzes5QEZzZ8X8RBg1jxMyAd-O4XryfmfSfN1_QMdZyAa
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BEaIXxJvlaSSuBsd2HPsIiGqBtqet1J4sO7GhUklQu3vov-9MHqvdCtQD18S2Jp5x5uGZbwDei-hcVWvJnWkarmMwPERXcxFc0MnqaAqqdz44NPMj_f24PN6ohaG0SvKh8wAU0f-r6XBTMHpKifso0cZHTV-ieyfxEYocatHbcKe01pCsi5P5Os6CIi2HK0uaxWnaVMjzr5W2VFSP5H8Nx_Rv1uj1pMoNLbX3AO6P5iX7NMjDQ7iV2kdwd2g4efkYTkY4JkZ1RKsL1mWGO0uAnJxKLiltiC04BfPZKRWOjOVZlwypYlO6AMMVwtkwqqZWRG33OzyBo72viy9zPjZX4HWp9JJTQWyZhcilLbTM0oVQoSrPxoiYm5QK3Lds6yInG2JK0qEpoGIjnLCNbaJQT2Gn7dr0HFjAv2qIKqKvaTUugB5czCrnXIRSV7mZgZ7209cj8jg1wDjzxQhQOrHBExv8yIYZfFhP-zNAb9w04TMxaz2YkLP7B935Tz8eRI_fFisZkTahkdjCaZGdTOhk0BWiLmfgNlntl33gJA9dTry6gYB3k1x4PKXEh9CmbnXh0cm12qHxh2OeDXKyJlMpYwg2cQbVlgRtfcf2m_b0V48EjtYWmnvFi_-g-S3cmy8O9v3-t8MfL2FXUsoORa_VK9hZnq_Sa7S5lvFNf6iuAJd4Hw8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCMQF8WbLy0hcDY7tJPaR12p5VRxaiZ4sO_FApZJU3d1D_31nEmfVrUA9cHVsa-IZe2bsmW8Yey2jc3VjlHBV2woTQyVCdI2QwQWTrIlVQfnO3_eqxYH58rOcogmXOaySfGgYgSKGs5o290kLU0TcW4UmPir6Er07hU0ocahEr7MbpUXzHEVaHi421ywo0Wp8saRRgoZNeTz_mmlLQw1A_pdgTP9mjF6OqbygpOZ32Z1sXfJ3ozjcY9dSd5_dHOtNnj1ghxmNiVMa0XrJe-C4sITHKSjjkqKG-L6gu3x-RHkjOTvrjCNVfIoW4DhDOB57NVSJqOv_hIfsYP5p_8NC5NoKoim1WQnKhy1BSihtYRQoF0KNmhyqSkZoUypw3cA2BSQbYkrKoSWgYyudtK1to9SP2E7Xd-kJ4wEP1RB1RFfTGpwAHbgIGgCKUJoa2hkz03r6JgOPU_2LY19kfNKJDZ7Y4DMbZuzNZtjJiLxx1YD3xKxNZwLOHhr6018-70OP_xZrFZE2aZDYwhkJTiX0MegF0ZQz5i6y2q-GexMYi5x4fQUBrya58LhJiQ-hS_166dHHtcah7Yd9Ho9ysiFT66oi1MQZq7ckaOs_tr90R78HIHA0ttDaK3b_g-aX7NaPj3P_7fPe16fstqKAHbq71s_Yzup0nZ6jxbWKL4Y9dQ6pdB44
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+status+of+antigen-specific+T-cell+immunotherapy+for+advanced+renal-cell+carcinoma&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Yuexin+Xu&rft.au=Chris+P.+Miller&rft.au=Edus+H.+Warren&rft.au=Scott+S.+Tykodi&rft.date=2021-07-03&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=17&rft.issue=7&rft.spage=1882&rft.epage=1896&rft_id=info:doi/10.1080%2F21645515.2020.1870846&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_fdeb72bf1a044f61940f92e772545845
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon